Reparixin

Drug Profile

Reparixin

Alternative Names: DF-1681Y; Repertaxin; Repertaxin L-Lysine salt

Latest Information Update: 07 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Dompe Farmaceutici; Fox Chase Cancer Center; SatRx; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Benzeneacetamides; Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Breast cancer; Liver transplant rejection
  • Discontinued Cerebral ischaemia

Most Recent Events

  • 28 Oct 2016 Phase-II clinical trials in Delayed graft function (Prevention) in Russia (IV) before October 2016 (Dompé pipeline, October 2016)
  • 28 Oct 2016 Dompé Farmaceutici and SatRx plan a phase II/III trial for Delayed graft function in liver transplant patients in Russia (Dompé website, October 2016)
  • 10 May 2016 Efficacy and adverse events data from a phase-II trial in Breast cancer (Early-stage, Monotherapy, Neoadjuvant therapy) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top